Susan Lee Trentham Tupper, 67, of Rockwood, Tennessee, formerly of Clinton, passed away on Tuesday, February 11, 2025, at ...

Nearly 3 months after the FDA green-lit the TTR stabilizer, it joins tafamidis as the second therapy in Europe for the ...

Scotiabank analyst Greg Harrison raised the firm’s price target on BridgeBio (BBIO) to $49 from $48 and keeps an Outperform rating on the ...

Shares of BridgeBio Pharma (NASDAQ:BBIO), currently valued at $5.88 billion, witnessed an uptick as Scotiabank (TSX:BNS) analyst Greg Harrison increased the price target to $49 from $48 while ...

The EU is the second market for the drug after the US, where it was approved under the Attruby brand name last November, on ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...

The European Commission has granted marketing authorization in the European Union (EU) for acoramidis, under the brand name ...

The approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most ...

H.C. Wainwright maintained its optimistic stance on Immix Biopharma , Inc. (NASDAQ:IMMX), with analyst Robert Burns reiterating a Buy rating and a $7.00 price target on the company's shares. Currently ...

Prothena (NASDAQ:PRTA – Free Report) had its price target boosted by Oppenheimer from $58.00 to $62.00 in a report published on Friday,Benzinga reports. They currently have an outperform rating on the ...

Europe's premier fintech showcase & meeting hotspot boasts 75+ speakers, thought leaders, and 1,000+ decision-makers sharing ...